JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/ AML1-ETO-positive AML

Leukemia. 2007 Jan;21(1):183-4. doi: 10.1038/sj.leu.2404465. Epub 2006 Nov 9.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Aged
  • Chromosomes, Human, Pair 21
  • Chromosomes, Human, Pair 8
  • Core Binding Factor Alpha 2 Subunit / genetics*
  • Female
  • Humans
  • Janus Kinase 2 / genetics*
  • Leukemia, Myeloid, Acute / drug therapy
  • Leukemia, Myeloid, Acute / genetics*
  • Male
  • Mutation*
  • Neoplasms, Second Primary / genetics
  • Oncogene Proteins, Fusion / genetics*
  • RUNX1 Translocation Partner 1 Protein
  • Translocation, Genetic

Substances

  • AML1-ETO fusion protein, human
  • Core Binding Factor Alpha 2 Subunit
  • Oncogene Proteins, Fusion
  • RUNX1 Translocation Partner 1 Protein
  • Janus Kinase 2